Literature DB >> 10964266

Inhibition of ethanol-induced liver disease in the intragastric feeding rat model by chlormethiazole.

Z Gouillon1, D Lucas, J Li, A L Hagbjork, B A French, P Fu, C Fang, M Ingelman-Sundberg, T M Donohue, S W French.   

Abstract

The purpose of this investigation was to assess the effect of chlormethiazole treatment on liver damage in the experimental rat intragastric ethanol-feeding model of alcoholic liver disease. Chlormethiazole has been used in the treatment of alcoholic withdrawal and has been shown to inhibit cytochrome P4502E1. Since treatment of experimental alcoholic liver disease with CYP2E1 inhibitors had an ameliorating effect on liver injury in the rat, chlormethiazole was used to see if it had a similar effect. Rats fed ethanol for 2 months had significantly less liver injury when chlormethiazole was added to the diet, fed intragastrically. The CYP2E1 apoprotein levels, which were increased by ethanol feeding, were also increased when chlormethiazole was fed with ethanol. Chlormethiazole inhibited the increase in the ethanol-induced CYP2E1 activity in vivo, as measured by chlorzoxazone 6-hydroxylation, but did not affect the level of CYP2E1 apoprotein. Likewise, the reduction in proteasome proteolytic enzyme activity produced by ethanol feeding was blunted in chlormethiazole-fed rats. These results support the conclusion that chlormethiazole treatment partially protects the liver from injury by inhibiting CYP2E1 activity in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964266     DOI: 10.1046/j.1525-1373.2000.22435.x

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  56 in total

1.  Proteasome inhibitor treatment in alcoholic liver disease.

Authors:  Fawzia Bardag-Gorce
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  The role of ethanol metabolism in development of alcoholic steatohepatitis in the rat.

Authors:  Martin J Ronis; Soheila Korourian; Michael L Blackburn; Jamie Badeaux; Thomas M Badger
Journal:  Alcohol       Date:  2010-01-29       Impact factor: 2.405

3.  Chlorzoxazone, an SK-type potassium channel activator used in humans, reduces excessive alcohol intake in rats.

Authors:  F Woodward Hopf; Jeffrey A Simms; Shao-Ju Chang; Taban Seif; Selena E Bartlett; Antonello Bonci
Journal:  Biol Psychiatry       Date:  2010-12-31       Impact factor: 13.382

Review 4.  Alcoholic Liver Disease: from CYP2E1 to CYP2A5.

Authors:  Tung Ming Leung; Yongke Lu
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

Review 5.  Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances.

Authors:  Mohamed A Abdelmegeed; Seung-Kwon Ha; Youngshim Choi; Mohammed Akbar; Byoung-Joon Song
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

Review 6.  Implication of altered proteasome function in alcoholic liver injury.

Authors:  Natalia A Osna; Terrence-M Donohue
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

7.  Retinoic Acid-mediated Nuclear Receptor Activation and Hepatocyte Proliferation.

Authors:  Nathan Bushue; Yu-Jui Yvonne Wan
Journal:  J Exp Clin Med       Date:  2009-12

8.  Ascorbic acid is superior to silymarin in the recovery of ethanol-induced inflammatory reactions in hepatocytes of guinea pigs.

Authors:  P A Abhilash; R Harikrishnan; M Indira
Journal:  J Physiol Biochem       Date:  2013-05-08       Impact factor: 4.158

9.  Alcohol Upregulation of CYP2A5: Role of Reactive Oxygen Species.

Authors:  Yongke Lu; Arthur I Cederbaum
Journal:  React Oxyg Species (Apex)       Date:  2016-03

10.  The antiapoptotic effects of different doses of β-carotene in chronic ethanol-fed rats.

Authors:  Hsiang-Chi Peng; Ya-Ling Chen; Shin-Yi Yang; Pei-Yin Ho; Sien-Sing Yang; Jui-Ting Hu; Suh-Ching Yang
Journal:  Hepatobiliary Surg Nutr       Date:  2013-06       Impact factor: 7.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.